WFA Asset Management Corp Has $40,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

WFA Asset Management Corp grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 61.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 255 shares of the company’s stock after purchasing an additional 97 shares during the quarter. WFA Asset Management Corp’s holdings in Johnson & Johnson were worth $40,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in JNJ. Mascoma Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 12.0% during the 3rd quarter. Mascoma Wealth Management LLC now owns 1,966 shares of the company’s stock worth $306,000 after acquiring an additional 210 shares during the last quarter. Key Bridge Compliance LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $1,090,000. Auour Investments LLC increased its holdings in shares of Johnson & Johnson by 32.2% during the 3rd quarter. Auour Investments LLC now owns 1,695 shares of the company’s stock worth $265,000 after acquiring an additional 413 shares during the last quarter. Summit Global Investments boosted its stake in Johnson & Johnson by 11.3% in the 3rd quarter. Summit Global Investments now owns 4,858 shares of the company’s stock valued at $757,000 after purchasing an additional 494 shares during the period. Finally, Sunflower Bank N.A. boosted its stake in Johnson & Johnson by 2.9% in the 3rd quarter. Sunflower Bank N.A. now owns 10,215 shares of the company’s stock valued at $1,591,000 after purchasing an additional 285 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $146.82 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The business has a 50-day simple moving average of $155.47 and a two-hundred day simple moving average of $155.41. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock has a market cap of $353.80 billion, a PE ratio of 9.15, a PEG ratio of 2.45 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.68 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 29.68%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, April 15th. Morgan Stanley reduced their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada cut their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.